ARCHIVES

FDA Breakthrough Designation Granted to Pfizer’s Palbociclib

This article is from The Cancer Letter archive.

Vol. 36 No. 4 | April 26, 2013

Download PDF Visit The Full Archive

Related Articles

ONS Votes to Push Congress on DRGs

June 1, 1984

Adding Topotecan To Standard Treatment Doesn’t Improve Progression-Free Survival

October 29, 2010

FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI

April 15, 1977

In Breif: Folkman selected For Karnofsky Lecture; Sporn to give ACS Lecture At ASCO

February 2, 1996

Daily Aspirin May Reduce Risk By 20 Percent, Study Says

February 28, 2014

NCAB Considering Concept Review Of Large, Expensive Investigator Initiated Proposals

February 16, 1990